Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price reached a new 52-week high on Thursday . The stock traded as high as C$11.40 and last traded at C$0.19, with a volume of 151642 shares trading hands. The stock had previously closed at C$0.19.
Devonian Health Group Price Performance
The stock has a market capitalization of C$1.91 billion, a price-to-earnings ratio of -250.00 and a beta of 0.91. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The stock has a 50-day simple moving average of C$0.42 and a 200 day simple moving average of C$0.26.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Featured Articles
- Five stocks we like better than Devonian Health Group
- A month before the crash
- Trump’s AI Secret: 100X Faster Than Nvidia
- Buy This Stock at 9:30 AM on MONDAY!
- A U.S. “birthright” claim worth trillions – activated quietly
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
